Kevin Bugin works for the FDA in the Office of New Drugs as the Director of Special Programs, leading various internally driven initiatives for the enhancement of the new drugs regulatory program. Prior to joining the FDA, Kevin Bugin worked in both industry and government in multiple areas of clinical research and development, such as regulatory affairs, safety and pharmacovigilance, technology transfer, and basic molecular biology research.